摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(Isopropylamino-methyl)-piperidin-1-yl]-ethanone | 1353979-33-5

中文名称
——
中文别名
——
英文名称
1-[4-(Isopropylamino-methyl)-piperidin-1-yl]-ethanone
英文别名
1-[4-[(propan-2-ylamino)methyl]piperidin-1-yl]ethanone
1-[4-(Isopropylamino-methyl)-piperidin-1-yl]-ethanone化学式
CAS
1353979-33-5
化学式
C11H22N2O
mdl
——
分子量
198.31
InChiKey
TTYBVMKQNQJIJE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.91
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
    申请人:Kusakabe Ken-ichi
    公开号:US20120059162A1
    公开(公告)日:2012-03-08
    Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.
    提供了一个由一般式(1)表示的化合物,具有TTK抑制作用,以及含有该化合物的药物。在式(1)中,(X,Y,V,W)为(—N═,═CR1—,═N—,—CR7═),(—CR2═,═N—,═N—,—CR7═),等等;A为(非)取代芳香烃环等;L为一个单键,—C(═O)—NRA—等;Z为由式—NR3R4或式—OR5表示的基团;R1至R3,R6和R7分别是氢原子等;R4和R5分别是(非)取代烷基等;R8是(非)取代环烷基等。
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    申请人:Ren Pingda
    公开号:US20130035324A1
    公开(公告)日:2013-02-07
    Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
  • METHODS OF USING EHMT2 INHIBITORS
    申请人:Epizyme, Inc.
    公开号:US20200113901A1
    公开(公告)日:2020-04-16
    The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
  • US9085560B2
    申请人:——
    公开号:US9085560B2
    公开(公告)日:2015-07-21
查看更多